Borrowing information across subgroups in phase II trials: Is it useful?

Clinical Cancer Research

Volumn 19, Issue 6, 2013, Pages 1326-1334

  Freidlin, Boris ^a   Korn, Edward L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BAYES THEOREM; CANCER PATIENT; CANCER RESEARCH; DATA ANALYSIS; DRUG EFFICACY; DRUG SCREENING; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEDICAL INFORMATION; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SAMPLE SIZE; SIMULATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BAYES THEOREM; CLINICAL TRIALS, PHASE II AS TOPIC; COMPUTER SIMULATION; HUMANS; MODELS, STATISTICAL; NEOPLASMS;

EID: 84875133582     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1223     Document Type: Article

References (19)

1. Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, et al. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res 2010;16:1764-9.
2. Chugh R, Wathen JK, Maki RG, Benjamin RS, Patel SR, Meyers PA, et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol 2009;27:3148-53.
3. Zhou X, Liu S, Kim ES, Herbst RS, Lee JJ. Bayesian adaptive design for targeted therapy development in lung cancer-a step toward personalized medicine. Clin Trials 2008;5:181-93.
4. Berry DA. Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis. Clin Trials 2005;2:295-300.
5. Hobbs BP, Carlin BP. Practical Bayesian design and analysis for drug and device clinical trials. J Biopharm Stat 2008;18:54-80.
6. Biswas S, Liu DD, Lee JJ, Berry DA. Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center. Clin Trials 2009;6:205-16.
7. Lindley DV, Smith AFM. Bayesian estimates for the linear model. J Royal Statist Soc Ser B 1972;34:1-41.
8. Kass RE, Steffey D. Approximate Bayesian inference in conditionally independent hierarchical models (parametric empirical Bayes models). J Am Statist Association 1989;84:717-726.
9. Thall PF, Wathen JK, Bekele BN, Champlin RE, Baker LH, Benjamin RS. Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes. Stat Med 2003;22:763-80.
10. Berry DA. A guide to drug discovery: Bayesian clinical trials. Nat Rev Drug Discov 2006;5:27-36.
11. LeBlanc M, Rankin C, Crowley J. Multiple histology phase II trials. Clin Cancer Res 2009;15;4256-62.
12. Carlin BP, Louis TA. Bayes and empirical Bayes methods for data analysis. 2nd ed. Boca Raton, FL; Chapman & Hall/CRC; 2000.
13. Berry SM, Carlin BP, Lee JJ, Muller P. Bayesian adaptive methods for clinical trials. Boca Raton, FL; Chapman & Hall/CRC; 2010.
14. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2011.
15. Spiegelhalter D, Thomas A, Best N, Bayesian Inference Using Gibbs Sampling Manual (BUGS 0.5) Cambridge, UK: MRC Biostatistics Unit; 1995.
16. United States Food and Drug Administration: 2010 draft guidance for industry on adaptive design clinical trials for drugs and biologics. [cited 2012 Jan 22]. Available from: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm201790.pdf.
17. Ibrahim JG, Chen M-H, Gray RJ. Bayesian models for gene expression with DNA microarray data. J Am Stat Associat 2002;97: 88-99.
18. Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Lee RJ, et al. PLX4032 in metastatic colorectal cancer patients with BRAF tumors. 2010 ASCO Annual Meeting. J Clin Oncol 28:15s, 2010 (suppl; abstr 3534).
19. Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009;27:3133-40.